BackTable / Urology / Podcast / Episode #268

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology

with Dr. Tyler Stewart

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.

This podcast is supported by:

Ferring Pharmaceuticals

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart on the BackTable Urology Podcast

Ep 268 Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart

00:00 / 01:04

BackTable, LLC (Producer). (2025, October 24). Ep. 268 – Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Bogdana Schmidt

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Dr. Tyler Stewart

Dr. Tyler Stewart is a medical oncologist and associate professor at UC San Diego Health in California.

Synopsis

The conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.

Timestamps

00:00 - Introduction
02:04 - The Role of Medical Oncologists in Bladder Cancer
12:58 - Combination Therapies and Patient Outcomes
21:18 - The CREST Study
26:59 - Managing Adverse Events
34:44 - Collaboration Between Urologists and Oncologists
41:06 - Conclusion and Final Thoughts

Resources

CREST Trial
https://www.nature.com/articles/s41591-025-03738-z

CISTO Study
https://pubmed.ncbi.nlm.nih.gov/37980511/

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill on the BackTable Urology Podcast

Guide to Patient-Centered Counseling in NMIBC Care with Dr. Sima Porten and Dr. Patrick Hensley on the BackTable Urology Podcast

Contemporary Diagnostics in NMIBC: Clinical Insights with Dr. Anne Schuckman and Dr. Piyush Agarwal on the BackTable Urology Podcast

Renal Cancer Management: Tumor Board Discussion & Treatments with Dr. Raquib Hannan, Dr. Brandon Manley and Dr. Rana McKay on the BackTable Urology Podcast

The Role of ctDNA in Bladder Cancer Diagnosis & Treatment with Dr. Alberto Pieretti on the BackTable Urology Podcast

Optimizing Bladder Health in BPH Treatment Strategies with Dr. Shawn West on the BackTable Urology Podcast

Articles

Topics

Non-Muscle Invasive Bladder Cancer (NMIBC) Condition Overview

Learn about Urologic Oncology on BackTable Urology

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.